Synthesis of interleukin 1β, tumor necrosis factor-α, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: Interactions with antiinflammatory cytokines

Journal of Rheumatology

Volumn 29, Issue 3, 2002, Pages 546-553

  He, Wendy ^a   Pelletier, Jean Pierre ^a   Martel Pelletier, Johanne ^a   Laufer, Stefan ^a   Di Battista, John A ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Collagenase; Eicosanoid; Inflammation; Leukotriene; Osteoarthritis

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; IONOMYCIN; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; THAPSIGARGIN; TUMOR NECROSIS FACTOR ALPHA; 2 (4 (QUINOLIN 2 YL METHOXY)PHENYL) 2 CYCLOPENTYLACETIC ACID; 2-(4-(QUINOLIN-2-YL-METHOXY)PHENYL)-2-CYCLOPENTYLACETIC ACID; INTERLEUKIN 1; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN E2; QUINOLINE DERIVATIVE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; INCUBATION TIME; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SYNOVIUM; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

AGED; CELLS, CULTURED; DINOPROSTONE; EICOSANOIDS; FIBROBLASTS; HUMANS; INTERLEUKIN-1; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; OSTEOARTHRITIS; QUINOLINES; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036009043     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Etiopathogenesis of osteoarthritis
2. Pathophysiologic aspects of inflammation in diarthroidal joints
3. Cytokines and inflammation in cartilage degradation
4. Biochemical factors in joint articular tissue degradation in osteoarthritis
5. 5-Lipoxygenase
6. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases
7. Eicosanoid production in rheumatoid synovitis
8. The mechanisms of action of NSAIDs in analgesia
9. NSAID therapy: Current concepts
10. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: Comparison with interleukin-1-synthesis inhibitors
11. 5-Lipoxygenase: Properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors
12. (6,7-diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenas
13. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase
14. Biosynthesis and biological activity of leukotriene B4
15. Involvement of leukotriene B4 in arthritis models
16. 4-induced interleukin-1β in synovial cells from patients with rheumatoid arthritis
17. Prostaglandin E2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1β treated synovial fibroblasts
18. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase
19. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site
20. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes
21. Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies
22. Evaluation of synovial cytokine patterns in rheumatoid arthritis and osteoarthritis by quantitative reverse transcription polymerase chain reaction
23. New induction of leukotriene A(4) hydrolase by interleukin-4 and interleukin-13 in human polymorphonuclear leukocytes
24. Role of leukotriene B4 in the interleukin-4-induced human mononuclear phagocyte activation
25. Contrasting effects of proinflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes
26. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells
27. Effect of IL-13 on cytokines, cytokine receptors and inhibitors on human osteoarthritic synovium and synovial fibroblasts
28. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee
29. Synovitis reduced by inhibition of leukotriene B4. Carrageenan-induced gonarthritis studied in dogs
30. Leukotriene B4 and prostaglandin E2-like activity in synovial fluid in osteoarthritis
31. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models
32. Lipoxygenase products and expression of 5-lipoxygenase and 5-lipoxygenase-activating protein in human cultured synovial cells
33. Leukotriene B4 in inflammation
34. 2 superfamily of signal transduction enzymes
35. 2 in human fibroblasts
36. Bacterial lipopolysaccharide activates nuclear factor-kappa B through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes
37. The human toll signaling pathway: Divergence of nuclear factor kappa B and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6)
38. Early growth response protein 1 (Egr-1): Prototype of a zinc-finger family of transcription factors
39. cAMP-response-element-binding-protein-binding protein (CBP) and p300 are transcriptional co-activators of early growth response factor-1 (Egr-1)
40. Suppression of tumor necrosis factor gene expression by prostaglandin E(2). Role of early growth response protein-1
41. 2 in human monocyte/macrophages. Elucidation of post-receptor signaling pathways
42. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs
43. Regulation of tumor necrosis factor-α and IL-1β synthesis by thromboxane A2 in nonadherent human monocytes
44. Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase-1 (proMMP-1) in human rheumatoid synovial fibroblasts
45. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-α, granulocyte-macrophage CSF, and IL-1β through prostaglandin-dependent and -independent mechanisms
46. 1 inhibit the cytokine-stimulated expression of metalloproteinases in normal human synovial fibroblasts: Mediation by cyclic AMP signalling pathway
47. Gene therapy for osteoarthritis: New perspectives for the twenty-first century
48. Interleukin 10-mediated inhibition of inflammatory cytokine production by human alveolar macrophages
49. Interleukin 13 suppresses cytokine production and stimulates the production of 15-HETE in PBMC. A comparison between IL-4 and IL-13
50. Interleukin-8 secretion and 15-lipoxygenase activity in rheumatoid arthritis: In vitro anti-inflammatory effects by interleukin-4 and interleukin-10, but not by interleukin-1 receptor antagonist protein
51. Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: Distinct targeting in the signaling pathways
52. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10